



Amendments to the Claims

1. (Currently Amended) A compound of the following formula:



or a pharmaceutically acceptable salt or N-oxide thereof;

wherein


A is 2-furanyl;

B is N;


each of R² and R³ is independently hydrogen or alkyl, ~~cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or heteroaralkyl~~;

each of X¹ and X² is independently ~~hydrogen~~, C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene or a bond;

L is a bond or a linker selected from the group consisting of:



Applicant(s): Chi Vu et al.
 U.S.S.N.: 10/552,306



wherein:

each of R' and R'' , independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thio, cyano, guanidino, amidino, carboxy, sulfo, sulfoxy, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl,

heteroaryloxy, heteroarylsulfanyl, or heteroaroyle; provided that two adjacent R' groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety;

X^a is -C(R²)(R³)-, -S-, -SO-, or -SO₂-;

X^b is -C(R²)(R³)-, -NR²-, -O-, -S-, -SO-, or -SO₂-;

each of p, q, m and m1, independently, is 0-3;

r is 1 or 2;

n1 is 0-6; and


n2 is 2-6;

Y is -C(R²)(R³)-, -O-, -S-, -SO-, -SO₂-, -CO-, -CO₂-, or a bond; and

R¹ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, or heterocycloalkyl;

provided that


(1) when each of X¹ is a bond and L is a 4- to 6-membered saturated heterocyclic group selected from the group consisting of:



(2) when L is a bond, X¹ is an alkynylene.

2. (Original) The compound of claim 1, wherein X¹ is C₂₋₆ alkynylene.


3. (Currently Amended) The compound of claim 2, wherein L is a bond, [[:]]




4. (Original) The compound of claim 2, wherein X² is C₁₋₄ alkylene or a bond.

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306


5. (Original) The compound of claim 2, wherein Y is a bond.
6. (Canceled)
7. (Original) The compound of claim 2, wherein R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.
8. (Original) The compound of claim 7, wherein R^1 is optionally substituted with alkyl, halo, hydroxy or phenyl.



9. (Currently Amended) The compound of claim 2, wherein L is a bond; X^2 is C_{1-4} alkylene or a bond; Y is a bond; ~~each of R^2 and R^3 is independently hydrogen or alkyl~~; R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; ~~A is heteroaryl~~; and B is N.



10. (Original) The compound of claim 1, wherein L is




11. (Original) The compound of claim 10, wherein X^b is $-C(R^2)(R^3)-$ or $-NR^2-$.
12. (Original) The compound of claim 11, wherein X^b is $-C(R^2)(R^3)-$.
13. (Original) The compound of claim 12, wherein p is 0-1 and q is 1.
14. (Original) The compound of claim 13, wherein n_1 is 1-4 and n_2 is 2-4.
15. (Original) The compound of claim 14, wherein X^1 is C_{1-6} alkylene or a bond.
16. (Original) The compound of claim 14, wherein X^2 is C_{1-6} alkylene or a bond.
17. (Original) The compound of claim 14, wherein Y is $-SO_2-$, $-CO-$, $-CO_2-$, or a bond.
18. (Canceled)

19. (Original) The compound of claim 14, wherein R^1 is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.


20. (Currently Amended) The compound of claim 14, wherein each of X^1 and X^2 is independently C_{1-6} alkylene or a bond; Y is $-SO_2-$, $-CO-$, $-CO_2-$, or a bond; ~~each of R^2 and R^3 is independently hydrogen or alkyl;~~ and R^1 is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.

21. (Currently Amended) The compound of claim 14, wherein L is



; X^1 is a bond, X^2 is C_{1-4} alkylene; Y is a bond; ~~each of R^2 and R^3 is independently hydrogen or alkyl;~~ R^1 is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; ~~A is heteroaryl;~~ and B is N.

22. (Original) The compound of claim 1, wherein L is



23. (Original) The compound of claim 22, wherein X^1 is C_{1-6} alkylene, C_{2-6} alkynylene, or a bond.

24. (Original) The compound of claim 22, wherein X^2 is C_{1-6} alkylene or a bond.

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

25. (Original) The compound of claim 22, wherein Y is $-\text{SO}_2-$, $-\text{CO}-$, $-\text{CO}_2-$, or a bond.

26. (Canceled)

27. (Original) The compound of claim 22, wherein R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

28. (Original) The compound of claim 27, wherein R^1 is optionally substituted with alkyl, halo, hydroxy or phenyl.

29. (Currently Amended) The compound of claim 22, wherein X^1 is C_{1-6} alkylene, C_{2-6} alkynylene, or a bond, X^2 is C_{1-6} alkylene or a bond; Y is $-\text{SO}_2-$, $-\text{CO}-$, $-\text{CO}_2-$, or a bond; ~~each of R^2 and R^3 is independently hydrogen or alkyl;~~ R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which is being optionally substituted with alkyl, halo, hydroxy, or phenyl; ~~A is heteroaryl;~~ and B is N.

30. (Original) The compound of claim 1, said compound being
2-furan-2-yl- N^5 -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-
[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;
2-furan-2-yl- N^5 -methyl- N^5 -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-
[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;
 N^5 -[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-
a]pyrimidine-5,7-diamine;
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-
a]pyrimidin-7-ylamine;
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]propyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-
a]pyrimidin-7-ylamine;
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-
a]pyrimidin-5,7-diamine;

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

N^5 -{2-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;
2-furan-2-yl- N^5 -(1-furan-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -[1-((2-fluorobenzyl)-pyrrolidin-2-ylmethyl)-2-furan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -(1-pyridin-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -(1-pyridin-4-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -(1-(2,3,6-trifluorobenzyl)-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -[1-(2-chloro-pyridin-4-ylmethyl)-pyrrolidin-2-ylmethyl)-2-furan-2-yl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclopentanol;
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclohexanol;
2-furan-2-yl- N^5 -{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(2,3-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -{2-[4-(3,4,5-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -{2-[4-(2,3,6-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(3,5-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(2,6-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(2,5-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

N^5 -{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -{2-[4-(2,4,5-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and
 N^5 -{2-[4-(4-chloro-2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine. [[:]]

31. (Original) The compound of claim 1, said compound being
2-furan-2-yl- N^5 -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -methyl- N^5 -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -(1-furan-2-ylmethyl-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl- N^5 -(1-(2,3,6-trifluorobenzyl)-pyrrolidin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -[1-(2-chloro-pyridin-4-ylmethyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-pentanol;
1-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)-cyclohexanol;
5-(3-cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;
N⁵-{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;
2-furan-2-yl-N⁵-{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
N⁵-{2-[4-(2,3-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
2-furan-2-yl-N⁵-{2-[4-(2,3,6-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
N⁵-{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
N⁵-{2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
N⁵-{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and
2-furan-2-yl-N⁵-{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine.

32. (Original) The compound of claim 1, said compound being

2-furan-2-yl-N⁵-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;
2-furan-2-yl-N⁵-methyl-N⁵-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;
N⁵-[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
5-(3-cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

N^5 -{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;
2-furan-2-yl- N^5 -{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;
 N^5 -{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and
2-furan-2-yl- N^5 -{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine.

33. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

34. (Original) A pharmaceutical composition comprising a compound of claim 30 and a pharmaceutically acceptable carrier.

35-46. (Canceled)

47. (Previously Presented) The compound of claim 10, wherein X^1 is C_{1-6} alkylene, C_{2-6} alkynylene or a bond.

48. (Previously Presented) The compound of claim 47, wherein R^2 is hydrogen or alkyl.

49. (Previously Presented) The compound of claim 48, wherein X^2 is C_{1-6} alkylene or a bond.

50. (Previously Presented) The compound of claim 49, wherein Y is $-SO_2-$, $-CO-$, $-CO_2-$, or a bond.

Applicant(s): Chi Vu et al.
U.S.S.N.: 10/552,306

51. (Previously Presented) The compound of claim 50, wherein R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

52. (Previously Presented) The compound of claim 51, wherein R^1 is a substituted aryl (e.g., 2,4-difluorophenyl).

53. (Previously Presented) The compound according to claim 10, wherein X^1 is C_{1-6} alkylene, C_{2-6} alkynylene or a bond; Y is $-SO_2-$, $-CO-$, $-CO_2-$, or a bond; R^1 is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl; and X^2 is C_{1-6} alkylene or a bond.